# A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

> **NCT07653100** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 540 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** RSVpreF
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07653100
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2027-01-25
- **Final completion:** 2027-01-25
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653100, "A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*